Extracorporeal Life Support Organization Registry Report 2012
Extracorporeal Life Support Organization Registry Report 2012
复制标题
DOI：
10.1097/mat.0b013e3182904a52
复制
发表时间：
2013-05-01
期刊：
影响因子：
4.2
通讯作者：
Thiagarajan, Ravi R.
中科院分区：
文献类型：
--
作者：
Paden, Matthew L.;Conrad, Steven A.;Thiagarajan, Ravi R.
本文介绍了截至 2012 年 7 月的年度国际体外生命支持组织 (ELSO) 注册报告的摘要数据。近 51,000 名患者接受了体外生命支持 (ECLS)。在这些患者中，50% (>25,000) 患有新生儿呼吸衰竭，出院或转院的总生存率为 75%。先天性膈疝仍然是 ECLS 在该人群中的主要用途，存活率为 51%。自 2000 年以来，用于治疗小儿呼吸衰竭的体外生命支持几乎增加了一倍，在过去 3 年的调查中，每年约有 350 名患者接受治疗（生存率为 56%）。此前十年，成人呼吸衰竭 ECLS 病例数一直稳定在每年约 100 例，但随着 2009 年 H1N1 流感大流行以及传统通气或 ECMO 治疗严重成人呼吸衰竭 (CESAR) 试验结果的公布，成人呼吸衰竭 ECLS 病例数急剧增加，到 2011 年一直保持在每年约 400 例（存活率 55%）。使用 ECLS 进行心脏支持代表了大范围的持续增长。大约 13,000 名患者接受了治疗，新生儿、儿童和成人的出院生存率分别为 40%、49% 和 39%。
In this article, summary data from the annual international Extracorporeal Life Support Organization (ELSO) Registry Reports through July 2012 are presented. Nearly 51,000 patients have received extracorporeal life support (ECLS). Of the patients, 50% (>25,000) were neonatal respiratory failure, with a 75% overall survival to discharge or transfer. Congenital diaphragmatic hernia remains a major use of ECLS in this population with 51% survival. Extracorporeal life support use for pediatric respiratory failure has nearly doubled since 2000, with approximately 350 patients treated per year in the past 3 years examined (56% survival). Previously stable at about 100 cases a year for a decade, adult respiratory failure ECLS cases increased dramatically in 2009 with the H1N1 influenza pandemic and publication of the Conventional ventilation or ECMO for Severe Adult Respiratory failure (CESAR) trial results and have remained at approximately 400 cases a year through 2011 (55% survival). Use of ECLS for cardiac support represents a large area of consistent growth. Approximately 13,000 patients have been treated with survival to discharge rates of 40%, 49%, and 39% for neonates, pediatric, and adults, respectively.